查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586047

癌症生物療法市場：依產品、給藥途徑和最終用戶 - 全球預測 2025-2030

Cancer Biological Therapy Market by Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines), Route of Administration (Intramuscular, Intravenous, Subcutaneous), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症生物治療市場價值為649.5億美元，預計到2024年將達到724.2億美元，複合年成長率為11.60%，到2030年將達到1400.4億美元，預計將達到1000萬美元。

癌症生物療法，也稱為免疫療法，包括單株抗體、疫苗和細胞激素療法等多種方法，利用人體的免疫系統來鎖定和對抗癌細胞。隨著癌症發生率持續上升，人們越來越需要比化療和放射線治療等傳統方法副作用更少的創新治療方法。這種生物學上多樣化的治療方法在多種癌症類型中具有重要的應用，包括黑色素瘤、乳癌和白血病。最終用途範圍主要包括醫院、專門的癌症治療中心和研究機構，可根據患者獨特的癌症特徵開發客製化的生物療法。

主要市場統計
基準年[2023] 649.5億美元
預測年份 [2024] 724.2億美元
預測年份 [2030] 1400.4億美元
複合年成長率（%） 11.60%

市場成長主要是由生技藥品管道的擴大和監管核准的增加以及生物技術的技術進步和對癌症基因組學的更深入了解所推動的。潛在的機會在於對個人化醫療的需求不斷成長，以及針對以前難以治療的癌症的新治療方法的快速開發。為了利用這一點，公司需要投資新一代抗體偶聯物和基於細胞的免疫療法的研究和開發。然而，該市場面臨高處理成本、複雜的製造流程和嚴格的監管要求等挑戰，這些都減緩了商業化進程。

可以透過增強藥物輸送系統來提高療效和患者便利性，並探索使用人工智慧進行個人化治療方法來推動創新。與研究機構合作開發生物相似藥和新型生物標記可能會進一步推動市場成長。市場仍然充滿活力，不斷突破，但為了保持競爭力，公司必須應對監管環境並管理成本障礙。透過專注於這些策略，公司可以有效參與新興趨勢、利用新技術並回應全球癌症患者不斷變化的需求。

市場動態：揭示快速發展的癌症生物治療市場的關鍵市場洞察

供需的動態交互作用正在改變癌症生物治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於醫療保健支出增加導致癌症盛行率增加
    • 提高人們對癌症生物治療益處的認知
    • 政府對癌症治療的優惠政策
  • 市場限制因素
    • 資本集中處理
  • 市場機會
    • 生物製藥的持續技術進步
    • 活性化旨在開發有效癌症生物療法的研究和開發
  • 市場挑戰
    • 抗癌藥物治療的效果

波特五力：駕馭癌症生物治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌症生物治療市場的外部影響

外部宏觀環境因素在塑造癌症生物治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症生物治療市場的競爭格局

對癌症生物治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣癌症生物治療市場供應商的績效評估

FPNV定位矩陣是評估癌症生物治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃癌症生物治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對癌症生物治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著醫療費用的增加，癌症發生率也會增加
      • 提高人們對癌症生物治療益處的認知
      • 政府對癌症治療的優惠政策
    • 抑制因素
      • 資本集中處理
    • 機會
      • 生物製藥的持續技術進步
      • 活性化研發活動以開發有效的生物癌症治療方法
    • 任務
      • 抗癌藥物治療的預期效果
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症生物治療市場：依產品

  • 癌症生長抑制劑
  • 單株抗體
  • 疫苗

第7章癌症生物治療市場：依途徑途徑

  • 肌肉注射
  • 靜脈
  • 皮下的

第8章癌症生物治療市場：依最終用戶分類

  • 醫院
  • 專業中心

第9章美洲癌症生物治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區癌症生物治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲癌症生物治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie, Inc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corp
  • Johnson & Johnson Services, Inc,
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • Sanofi SA
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-B72AD18D0F9C

The Cancer Biological Therapy Market was valued at USD 64.95 billion in 2023, expected to reach USD 72.42 billion in 2024, and is projected to grow at a CAGR of 11.60%, to USD 140.04 billion by 2030.

Cancer biological therapy, often known as immunotherapy, leverages the body's immune system to target and combat cancer cells, encompassing various modalities like monoclonal antibodies, vaccines, and cytokine therapies. As the incidence of cancer continues to rise, there is an increasing necessity for innovative treatments that offer fewer side effects than traditional methods like chemotherapy and radiation. This biologically diverse therapeutic approach has significant applications across numerous cancer types, including melanoma, breast cancer, and leukemia, to name a few. The end-use scope primarily includes hospitals, specialized cancer treatment centers, and research institutes, where tailored biological therapies can be developed based on patient-specific cancer profiles.

KEY MARKET STATISTICS
Base Year [2023] USD 64.95 billion
Estimated Year [2024] USD 72.42 billion
Forecast Year [2030] USD 140.04 billion
CAGR (%) 11.60%

Market growth is largely influenced by technological advancements in biotechnology and a deeper understanding of cancer genomics, alongside an expanding pipeline of biologics and increasing regulatory approvals. The potential opportunities lie in the rising demand for personalized medicine and the rapid development of new therapies addressing previously hard-to-treat cancers. To capitalize on this, companies should invest in R&D for next-generation antibody-drug conjugates and cell-based immunotherapies. However, the market faces challenges such as high treatment costs, complex manufacturing processes, and stringent regulatory requirements that can delay commercialization.

Innovation can be driven by enhancing drug delivery systems to improve efficacy and patient convenience, and exploring the use of artificial intelligence for personalized treatment regimens. Collaborations with research institutions to develop biosimilars and novel biomarkers could further propel market growth. The market remains dynamic, marked by continuous breakthroughs but requires companies to navigate regulatory landscapes adeptly and manage cost barriers to maintain competitiveness. By focusing on these strategies, businesses can effectively engage with emerging trends, leverage new technologies, and address the evolving needs of cancer patients globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biological Therapy Market

The Cancer Biological Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of cancer with increased healthcare expenditure
    • Increasing awareness regarding benefits of cancer biological therapy
    • Favorable government policies for cancer based therapies
  • Market Restraints
    • Capital intensive treatment
  • Market Opportunities
    • Ongoing technological advancements in cancer biologics
    • Rising research and development activities for development of efficient cancer biological therapies
  • Market Challenges
    • Probable effects of anti-cancer drug therapy

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biological Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biological Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biological Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biological Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biological Therapy Market

A detailed market share analysis in the Cancer Biological Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biological Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biological Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biological Therapy Market

A strategic analysis of the Cancer Biological Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biological Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Biogen Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc,, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Cancer Biological Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Cancer Growth Blockers, Monoclonal Antibodies, and Vaccines.
  • Based on Route of Administration, market is studied across Intramuscular, Intravenous, and Subcutaneous.
  • Based on End-Users, market is studied across Hospitals and Specialty Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of cancer with increased healthcare expenditure
      • 5.1.1.2. Increasing awareness regarding benefits of cancer biological therapy
      • 5.1.1.3. Favorable government policies for cancer based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancements in cancer biologics
      • 5.1.3.2. Rising research and development activities for development of efficient cancer biological therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Probable effects of anti-cancer drug therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biological Therapy Market, by Product

  • 6.1. Introduction
  • 6.2. Cancer Growth Blockers
  • 6.3. Monoclonal Antibodies
  • 6.4. Vaccines

7. Cancer Biological Therapy Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Intravenous
  • 7.4. Subcutaneous

8. Cancer Biological Therapy Market, by End-Users

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Centers

9. Americas Cancer Biological Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Biological Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biological Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. bluebird bio, Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Eisai Co., Ltd.
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche Ltd
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline PLC
  • 15. Hikma Pharmaceuticals PLC
  • 16. Incyte Corp
  • 17. Johnson & Johnson Services, Inc,
  • 18. Merck & Co., Inc.
  • 19. Novartis AG
  • 20. Otsuka Pharmaceutical Co., Ltd
  • 21. Pfizer Inc.
  • 22. Sanofi SA
  • 23. Spectrum Pharmaceuticals, Inc.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. CANCER BIOLOGICAL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOLOGICAL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023